 |
|
|
|
|
|
|
| Article 1 to 10 out of 31 concerning Pfizer Inc.
|
-
EPA Honors Pfizer for Reducing Greenhouse Gas Emissions
(10 Oct 2008)
Company Exceeds Initial Goal - Pledges 20 Percent Reduction Between Now and 2012
The U.S. Environmental Protection Agency (EPA) honored Pfizer Inc in recognition of the company’s award-winning Energy and Climate Change Program, which reduced total greenhouse gas emissions by 43 percent per million dollars of revenue from 2000 to ...
-
Scandal in the Pharmaceutical World
(30 Jun 2008)
A large number of the world's largest pharmaceutical companies have illegally used, and profited from, a groundbreaking patent stolen from Nogdan Immunochemicals Ltd., an Israeli biotech company
Nogdan Immunochemicals Ltd.and Mr. Roland Taieb, the exclusive owner of the patent's marketing rights worldwide, announced that many of the world's largest pharmaceutical companies are embroiled in the legal dispute concerning their groundbreaking ...
-
Hikal signs a manufacturing agreement with Pfizer
(09 Jan 2008)
Hikal Ltd. announced that it has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (API's) with Pfizer Inc."We are extremely pleased to be selected as a long term contract manufacturer by Pfizer", said Jai ...
-
Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
(08 Jan 2008)
Pfizer Inc and Taisho Pharmaceutical Co., Ltd. have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize ...
-
Pfizer to Acquire Coley Pharmaceutical Group
(22 Nov 2007)
Acquisition Will Expand Pfizer's Investment in Vaccines
Pfizer Inc announced it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc., a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to ...
-
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
(29 Aug 2007)
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
Pfizer Inc and Bristol-Myers Squibb Company announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT-1 discovery program includes advanced ...
-
High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011
(12 Jul 2007)
Pfizer Inc said that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is ...
-
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
(22 May 2007)
Company to Focus on Accelerating Development and Commercialization of Strong Early- and Mid-Stage Pipeline
Pfizer said that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company's research division throughout his 30-year career, will retire from Pfizer by the end of this year. ...
-
Pfizer Board of Directors Elects Constance J. Horner to Serve as Lead Director
(27 Feb 2007)
Pfizer said that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective February 23. She succeeds Dr. Stanley O. Ikenberry, who has announced plans to retire from the board effective ...
-
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
(15 Feb 2007)
Pfizer announced that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant ...
|
|
|
|
|
Top